And we’re off!
No, no, not to the races – and certainly not to Cheltenham – but rather it’s that time of the year when the first of our annual AACR Preview series drops. While some cancer conferences have been postponed and even cancelled, others such as AACR and ASCO are proceeding with virtual meetings, proving that even dark times can offer hints of hope.
This is good news for both young researchers and companies alike in getting data out there and shared because life goes on as time and tide wait for no man.
The actual abstracts themselves won’t be revealed until later in the month on April 27th, but for now we get a taster of this year’s truncated event since the titles available for the first virtual meeting.
Often time, this glimpse is sufficient to garner some useful clues, so what does this year hold in store for us all?
This Preview series will be in multiple parts – a review of some of the key oral sessions from the first virtual program (targeted agents, immunotherapies, cell therapies, novel targets, translational studies etc) followed by a review of the posters in the final part.
To get started, let’s take a look at some of the important presentations we can expect to hear on the first day…